Sökning: onr:"swepub:oai:gup.ub.gu.se/309245" > Modelling human liv...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04043naa a2200637 4500 | |
001 | oai:gup.ub.gu.se/309245 | |
003 | SwePub | |
008 | 240910s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/3092452 URI |
024 | 7 | a https://doi.org/10.1038/s42003-021-02616-x2 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Kostrzewski, T.4 aut |
245 | 1 0 | a Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system |
264 | c 2021-09-15 | |
264 | 1 | b Springer Science and Business Media LLC,c 2021 |
520 | a Kostrzewski et al. introduce an in vitro microphysiological model of non-alcoholic steatohepatitis (NASH), consisting of co-cultured primary human liver cells. The authors characterised the transcriptomic, inflammatory and fibrotic phenotype of the model and show that major features of NASH can be recapitulated and therapeutic interventions mimicked. Non-alcoholic steatohepatitis (NASH) is a common form of chronic liver disease characterised by lipid accumulation, infiltration of immune cells, hepatocellular ballooning, collagen deposition and liver fibrosis. There is a high unmet need to develop treatments for NASH. We have investigated how liver fibrosis and features of advanced clinical disease can be modelled using an in vitro microphysiological system (MPS). The NASH MPS model comprises a co-culture of primary human liver cells, which were cultured in a variety of conditions including+/- excess sugar, fat, exogenous TGF beta or LPS. The transcriptomic, inflammatory and fibrotic phenotype of the model was characterised and compared using a system biology approach to identify conditions that mimic more advanced clinical disease. The transcriptomic profile of the model was shown to closely correlate with the profile of patient samples and the model displayed a quantifiable fibrotic phenotype. The effects of Obeticholic acid and Elafibranor, were evaluated in the model, as wells as the effects of dietary intervention, with all able to significantly reduce inflammatory and fibrosis markers. Overall, we demonstrate how the MPS NASH model can be used to model different aspects of clinical NASH but importantly demonstrate its ability to model advanced disease with a quantifiable fibrosis phenotype. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a term-follow-up | |
653 | a obeticholic acid | |
653 | a preclinical models | |
653 | a disease | |
653 | a pathogenesis | |
653 | a multicenter | |
653 | a progression | |
653 | a cirrhosis | |
653 | a patterns | |
653 | a agonist | |
653 | a Life Sciences & Biomedicine - Other Topics | |
653 | a Science & Technology - Other | |
653 | a Topics | |
700 | 1 | a Snow, S.4 aut |
700 | 1 | a Battle, A. L.4 aut |
700 | 1 | a Peel, S.4 aut |
700 | 1 | a Ahmad, Z.4 aut |
700 | 1 | a Basak, J.4 aut |
700 | 1 | a Surakala, M.4 aut |
700 | 1 | a Bornot, A.4 aut |
700 | 1 | a Lindgren, J.4 aut |
700 | 1 | a Ryaboshapkina, M.4 aut |
700 | 1 | a Clausen, M.4 aut |
700 | 1 | a Lindén, Daniel,d 1971u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology4 aut |
700 | 1 | a Maass, C.4 aut |
700 | 1 | a Young, L. M.4 aut |
700 | 1 | a Corrigan, A.4 aut |
700 | 1 | a Ewart, L.4 aut |
700 | 1 | a Hughes, D.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi4 org |
773 | 0 | t Communications Biologyd : Springer Science and Business Media LLCg 4:1q 4:1x 2399-3642 |
856 | 4 | u https://www.nature.com/articles/s42003-021-02616-x.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/309245 |
856 | 4 8 | u https://doi.org/10.1038/s42003-021-02616-x |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy